Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 652

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 652
---
 the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provided
a reasonable basis for our opinion.

/s/
Cherry Bekaert LLP

We
served as the Company’s auditor from 2023 to 2024.

Tampa,
Florida

March
29, 2024

F-2

Telomir
Pharmaceuticals, Inc.

BALANCE
SHEETS

    December
    31,  
    December
    31, 

    2024  
    2023 
  
    ASSETS 

    Current assets: 

    Cash 
    $1,266,131  
    $1,231 
  
    Deferred offering costs 
     -  
     303,281 
  
    Prepaid expenses 
     57,874  
     713 
  
    Due
    from related parties 
     -  
     130,000 
  
    Total current assets 
     1,324,005  
     435,225 

    Deferred financing costs 
     -  
     4,338,543 

    Total
    assets 
    $1,324,005  
    $4,773,768 

    LIABILITIES AND STOCKHOLDERS’
    EQUITY 

    Current liabilities: 

    Trade accounts